Document is current

Article History

Received: 8 August 2022

Accepted: 10 March 2023

First Online: 20 April 2023

Declarations

:

: The study (NCT02795650) was approved by the Comité Ético de Investigación Clínica Regional de la Comunidad de Madrid (CEIC-R) and the Vall d’Hebron Institute of Research (VHIR) Ethics Committees. The research was conducted in accordance with the Declaration of Helsinki and local data protection laws. All patients provided written informed consent before enrollment. All data provided were anonymised in line with applicable laws and regulations.The animal work was approved by the Comité de Ética de la Investigación de la Universidad Rey Juan Carlos.

: Not applicable.

: The affiliations of F.S. and C.A. with Peaches Biotech represent no conflict of interest with the study. M.H. is a member of the board of directors for Bristol Myers Squibb; is a founder of Champions Oncology, Inc., and Nelum Inc.; holds stock options for Champions Oncology, Inc.; InxMed; Biooncotech; and Bristol Myers Squibb; has received research support from Agenus; has received honoraria from InxMed, Oncomatrix, MiNKi, and Peaches Biotech; and has received royalties from Myriad and Khar. None of these represents a direct conflict of interest. N.M. has stock options in and has consulted for Achilles Therapeutics. N.M holds European patents relating to targeting neoantigens (PCT/EP2016/ 059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), and predicting survival rates of patients with cancer (PCT/GB2020/050221). The remaining authors declare that they have no competing interests.